{"id":745321,"date":"2016-10-08T07:45:00","date_gmt":"2016-10-08T07:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\/"},"modified":"2025-11-07T01:25:37","modified_gmt":"2025-11-07T06:25:37","slug":"merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\/","title":{"rendered":"Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress"},"content":{"rendered":"<p class=\"bwalignc\">       Data Comparing KEYTRUDA to Chemotherapy Shows Continued Benefit with        Follow-Up Beyond 2.5 Years&nbsp;in Patients with Ipilimumab-Refractory        Advanced Melanoma     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced findings from the final overall survival (OS) analysis<br \/>\n      from the KEYNOTE-002 study investigating the use of KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, compared to<br \/>\n      investigator-choice chemotherapy with a crossover to KEYTRUDA design, in<br \/>\n      patients with ipilimumab-refractory advanced melanoma. Results presented<br \/>\n      at the ESMO 2016 Congress, the annual meeting of the European Society<br \/>\n      for Medical Oncology, in Copenhagen include follow-up of up to 35 months<br \/>\n      for the study\u2019s co-primary endpoints of OS and progression-free survival<br \/>\n      (PFS). Data showed prolonged OS with KEYTRUDA (2 mg\/kg and 10 mg\/kg),<br \/>\n      with a median OS of 13.4 months and 14.7 months and a two-year OS rate<br \/>\n      of 35.9 percent and 38.2 percent, respectively, compared to a median OS<br \/>\n      of 11.0 months and a two-year OS rate of 29.7 percent with chemotherapy.\n    <\/p>\n<p>\n      \u201cNow, with longer follow-up, we continue to show clinically meaningful<br \/>\n      outcomes with KEYTRUDA as monotherapy in these ipilimumab-refractory<br \/>\n      patients,\u201d said Dr. Roger Dansey, senior vice president, oncology<br \/>\n      late-stage development, Merck Research Laboratories. \u201cThese results<br \/>\n      provide further evidence supporting the use of KEYTRUDA as a standard of<br \/>\n      care for patients with advanced melanoma.\u201d\n    <\/p>\n<p>\n      Today, KEYTRUDA is approved for the treatment of advanced melanoma in<br \/>\n      more than 50 countries, including the United States and throughout<br \/>\n      Europe. The KEYTRUDA clinical development program includes more than 30<br \/>\n      tumor types in more than 350 clinical studies, including more than 100<br \/>\n      trials that combine KEYTRUDA (pembrolizumab) with other cancer<br \/>\n      treatments.\n    <\/p>\n<p>\n      The final analysis from KEYNOTE-002 is being presented at the ESMO 2016<br \/>\n      Congress by Dr. Omid Hamid, director of the Melanoma Center at The<br \/>\n      Angeles Clinic and Research Institute, on Oct. 8 from 2:45 &#8211; 4:15 p.m.<br \/>\n      CEST (Abstract: #1107O).\n    <\/p>\n<p>\n      <b>Additional Findings from KEYNOTE-002<\/b>\n    <\/p>\n<p>\n      KEYNOTE-002 is a multicenter, randomized, controlled phase 2 study of<br \/>\n      KEYTRUDA (2 mg\/kg or 10 mg\/kg every three weeks) compared to<br \/>\n      investigator\u2019s choice chemotherapy (paclitaxel plus carboplatin,<br \/>\n      paclitaxel, carboplatin, dacarbazine, or temozolomide) in patients with<br \/>\n      ipilimumab-refractory advanced melanoma (n=540). The co-primary<br \/>\n      endpoints were PFS and OS; secondary endpoints included overall response<br \/>\n      rate (ORR), duration of response, and safety. Tumor response was<br \/>\n      assessed at week 12, then every six weeks through week 48, followed by<br \/>\n      every 12 weeks thereafter as assessed by independent central review<br \/>\n      using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Per<br \/>\n      the study protocol, after three months, patients who experienced disease<br \/>\n      progression on the chemotherapy arm were eligible to cross over to<br \/>\n      receive KEYTRUDA. In total, 55 percent (n=98\/179) of patients in the<br \/>\n      chemotherapy arm crossed over to receive KEYTRUDA monotherapy.\n    <\/p>\n<p>\n      In the final analysis, which included the 98 patients who crossed over<br \/>\n      from the chemotherapy arm to receive KEYTRUDA, the median OS was 13.4<br \/>\n      months with KEYTRUDA 2 mg\/kg (95% CI, 11.0-16.4 months) and 14.7 months<br \/>\n      with KEYTRUDA 10 mg\/kg (95% CI 11.3-19.5 months), compared to 11.0<br \/>\n      months with chemotherapy (95% CI, 8.9-13.8 months) (hazard ratio: 0.86<br \/>\n      [95% CI, 0.67-1.10; p=0.1173] and hazard ratio: 0.74 [95% CI, 0.57-0.96;<br \/>\n      p=0.0106], respectively); the two-year (24-month) OS rate was 35.9<br \/>\n      percent and 38.2 percent with KEYTRUDA (2 mg\/kg and 10 mg\/kg,<br \/>\n      respectively), compared to 29.7 percent with chemotherapy.\n    <\/p>\n<p>\n      While improvements in OS between KEYTRUDA (2 mg\/kg or 10 mg\/kg) and<br \/>\n      chemotherapy did not meet the protocol-specified significance threshold,<br \/>\n      longer follow-up continued to show a clinically meaningful improvement<br \/>\n      in PFS, the study\u2019s co-primary endpoint, with PFS of up to 31 months in<br \/>\n      patients treated with KEYTRUDA. Median PFS was approximately three<br \/>\n      months for each of the patient groups (95% CI of 2.8-3.8 months with<br \/>\n      KEYTRUDA 2 mg\/kg; 95% CI of 2.8-5.2 months with KEYTRUDA 10 mg\/kg; and<br \/>\n      95% CI of 2.6-2.8 months with chemotherapy) (hazard ratio: 0.58 [95% CI,<br \/>\n      0.46-0.73; p&lt;0.0001] and hazard ratio: 0.47 [95% CI, 0.37-0.60;<br \/>\n      p&lt;0.0001], respectively). The two-year PFS rate was 16.0 percent and<br \/>\n      21.9 percent with KEYTRUDA (pembrolizumab) (2 mg\/kg and 10 mg\/kg,<br \/>\n      respectively), compared to less than one percent (0.6 percent) of<br \/>\n      patients treated with chemotherapy.\n    <\/p>\n<p>\n      ORR was 22.2 percent and 27.6 percent with KEYTRUDA (2 mg\/kg and 10<br \/>\n      mg\/kg, respectively), compared to 4.5 percent with chemotherapy. At the<br \/>\n      time of analysis, 50 percent and 58 percent of patients who responded to<br \/>\n      KEYTRUDA (2 mg\/kg and 10 mg\/kg, respectively) were alive with no<br \/>\n      subsequent progression or anti-tumor therapy, compared to 12 percent of<br \/>\n      patients who responded to chemotherapy.\n    <\/p>\n<p>\n      With longer follow-up, adverse events have remained consistent with<br \/>\n      previously reported safety data. Treatment-related immune-mediated<br \/>\n      adverse events of Grade 3-4 were pneumonitis, colitis (10 mg\/kg only),<br \/>\n      adrenal insufficiency, severe skin toxicity, hypophysitis, hepatitis,<br \/>\n      nephritis (2 mg\/kg only), pancreatitis (10 mg\/kg only), and myasthenia<br \/>\n      (10 mg\/kg only).\n    <\/p>\n<p>\n      <b>About Melanoma<\/b>\n    <\/p>\n<p>\n      Melanoma, the most serious form of skin cancer, is characterized by the<br \/>\n      uncontrolled growth of pigment-producing cells. The incidence of<br \/>\n      melanoma has been increasing over the past four decades \u2013 approximately<br \/>\n      232,000 new cases were diagnosed worldwide in 2012. In the U.S.,<br \/>\n      melanoma is one of the most common types of cancer diagnosed and is<br \/>\n      responsible for the vast majority of skin cancer deaths. In 2016, an<br \/>\n      estimated 76,380 people are expected to be diagnosed and an estimated<br \/>\n      10,130 people are expected to die of the disease in the U.S. alone. The<br \/>\n      five-year survival rates for advanced or metastatic melanoma (Stage IV)<br \/>\n      are estimated to be 15 to 20 percent.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab) Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a dose of 2 mg\/kg every three weeks.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy, at a dose of 2 mg\/kg every three<br \/>\n      weeks. Patients with EGFR or ALK genomic tumor aberrations should have<br \/>\n      disease progression on FDA-approved therapy for these aberrations prior<br \/>\n      to receiving KEYTRUDA. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response. An<br \/>\n      improvement in survival or disease-related symptoms has not yet been<br \/>\n      established. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy at a fixed dose<br \/>\n      of 200 mg every three weeks. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<br \/>\n      in Melanoma<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis, including fatal cases, occurred in patients<br \/>\n      receiving KEYTRUDA. Pneumonitis occurred in 32 (2.0%) of 1567 patients,<br \/>\n      including Grade 1 (0.8%), 2 (0.8%), and 3 (0.4%) pneumonitis. Monitor<br \/>\n      patients for signs and symptoms of pneumonitis. Evaluate suspected<br \/>\n      pneumonitis with radiographic imaging. Administer corticosteroids for<br \/>\n      Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2;<br \/>\n      permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 31 (2%) of 1567 patients, including<br \/>\n      Grade 2 (0.5%), 3 (1.1%), and 4 (0.1%) colitis. Monitor patients for<br \/>\n      signs and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA (pembrolizumab) for Grade 2 or 3;<br \/>\n      permanently discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in 16 (1%) of 1567 patients,<br \/>\n      including Grade 2 (0.1%), 3 (0.7%), and 4 (0.1%) hepatitis. Monitor<br \/>\n      patients for changes in liver function. Administer corticosteroids for<br \/>\n      Grade 2 or greater hepatitis and, based on severity of liver enzyme<br \/>\n      elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 13 (0.8%) of 1567 patients, including Grade 2<br \/>\n      (0.3%), 3 (0.3%), and 4 (0.1%) hypophysitis. Monitor patients for signs<br \/>\n      and symptoms of hypophysitis (including hypopituitarism and adrenal<br \/>\n      insufficiency). Administer corticosteroids and hormone replacement as<br \/>\n      clinically indicated. Withhold KEYTRUDA for Grade 2; withhold or<br \/>\n      discontinue for Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 51 (3.3%) of 1567 patients, including Grade<br \/>\n      2 (0.6%) and 3 (0.1%) hyperthyroidism. Hypothyroidism occurred in 127<br \/>\n      (8.1%) of 1567 patients, including Grade 3 (0.1%) hypothyroidism.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in 7 (0.4%) of 1567 patients,<br \/>\n      including Grade 2 (0.2%), 3 (0.2%), and 4 (0.1%) nephritis. Monitor<br \/>\n      patients for changes in renal function. Administer corticosteroids for<br \/>\n      Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA (pembrolizumab) when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 1567 patients:<br \/>\n      arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis,<br \/>\n      myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis, vasculitis,<br \/>\n      pancreatitis, hemolytic anemia, and partial seizures arising in a<br \/>\n      patient with inflammatory foci in brain parenchyma.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-002, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      12% of 357 patients; the most common (\u22651%) were general physical health<br \/>\n      deterioration (1%), asthenia (1%), dyspnea (1%), pneumonitis (1%), and<br \/>\n      generalized edema (1%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 14% of patients; the most common (\u22651%) were dyspnea<br \/>\n      (1%), diarrhea (1%), and maculopapular rash (1%). The most common<br \/>\n      adverse reactions with KEYTRUDA vs chemotherapy were fatigue (43% with<br \/>\n      KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%), constipation (22% vs<br \/>\n      20%), nausea (22% with KEYTRUDA), diarrhea (20% vs 20%), and decreased<br \/>\n      appetite (20% with KEYTRUDA). Corresponding incidence rates are listed<br \/>\n      for chemotherapy only for those adverse reactions that occurred at the<br \/>\n      same or lower rate than with KEYTRUDA\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 350 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51435625&amp;newsitemid=20161008005027&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=cff8f4e34fc0eeb6f5f44a0bee017ac9\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51435625&amp;newsitemid=20161008005027&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=6ffb7c44adfaa27b13e12d93d6bc794c\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51435625&amp;newsitemid=20161008005027&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=a88a6844a74790f5604d986604d928d1\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51435625&amp;newsitemid=20161008005027&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=6c8af7302efbbac3766e6b8913c93442\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51435625&amp;newsitemid=20161008005027&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=b12593305e2e1ae62a4b2c3d5d65ea04\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51435625&amp;newsitemid=20161008005027&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=5481213051370e2785e4225577625e94\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. If underlying assumptions prove<br \/>\n      inaccurate or risks or uncertainties materialize, actual results may<br \/>\n      differ materially from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51435625&amp;newsitemid=20161008005027&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=2fa95ad2148c6d39270a98eb652200da\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51435625&amp;newsitemid=20161008005027&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=67ca25f0f1b4e2f0b6f63dd3d6080172\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51435625&amp;newsitemid=20161008005027&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=846d7377e6c74ed947405b859719091b\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161008005027r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Kim        Hamilton, 908-740-1863<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from the final overall survival (OS) analysis from the KEYNOTE-002 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, compared to investigator-choice chemotherapy with a crossover to KEYTRUDA design, in patients with ipilimumab-refractory advanced melanoma. Results presented at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology, in Copenhagen include follow-up of up to 35 months for the study\u2019s co-primary endpoints of OS and progression-free survival (PFS). Data showed prolonged OS with KEYTRUDA (2 mg\/kg and 10 mg\/kg), with a median OS of 13.4 months and 14.7 months and a two-year OS rate of 35.9 percent and 38.2 percent, respectively, compared to a median OS of 11.0 months and a two-year OS rate of 29.7 percent with chemotherapy. \u201cNow, with longer follow-up, we continue to show clinically meaningful outcomes with<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289,56],"class_list":["post-745321","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from the final overall survival (OS) analysis from the KEYNOTE-002 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, compared to investigator-choice chemotherapy with a crossover to KEYTRUDA design, in patients with ipilimumab-refractory advanced melanoma. Results presented at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology, in Copenhagen include follow-up of up to 35 months for the study\u2019s co-primary endpoints of OS and progression-free survival (PFS). Data showed prolonged OS with KEYTRUDA (2 mg\/kg and 10 mg\/kg), with a median OS of 13.4 months and 14.7 months and a two-year OS rate of 35.9 percent and 38.2 percent, respectively, compared to a median OS of 11.0 months and a two-year OS rate of 29.7 percent with chemotherapy. \u201cNow, with longer follow-up, we continue to show clinically meaningful outcomes with\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\\\/\",\"name\":\"Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-10-08T07:45:00+00:00\",\"dateModified\":\"2025-11-07T06:25:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from the final overall survival (OS) analysis from the KEYNOTE-002 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, compared to investigator-choice chemotherapy with a crossover to KEYTRUDA design, in patients with ipilimumab-refractory advanced melanoma. Results presented at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology, in Copenhagen include follow-up of up to 35 months for the study\u2019s co-primary endpoints of OS and progression-free survival (PFS). Data showed prolonged OS with KEYTRUDA (2 mg\/kg and 10 mg\/kg), with a median OS of 13.4 months and 14.7 months and a two-year OS rate of 35.9 percent and 38.2 percent, respectively, compared to a median OS of 11.0 months and a two-year OS rate of 29.7 percent with chemotherapy. \u201cNow, with longer follow-up, we continue to show clinically meaningful outcomes with","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:37+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\/","name":"Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-10-08T07:45:00+00:00","dateModified":"2025-11-07T06:25:37+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presented-at-esmo-2016-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"182ec308-c8f0-4270-9b49-c67a1aef7eac","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Longer-Term-Follow-Up-of-Overall-Survival-Data-for-KEYTRUDA-pembrolizumab-in-Patients-with-Advanced-Melanoma-from-KEY-VQ69F.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745321\/revisions"}],"predecessor-version":[{"id":3674728,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745321\/revisions\/3674728"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745321"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}